Financials Blonder Tongue Laboratories, Inc.

Equities

BDRL

US0936981085

Communications & Networking

Delayed OTC Markets 12:29:19 2024-04-29 pm EDT 5-day change 1st Jan Change
0.1002 USD -22.92% Intraday chart for Blonder Tongue Laboratories, Inc. -46.70% +22.94%

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 4.923 10.26 7.322 15.37 7.565 2.567
Enterprise Value (EV) 1 11.21 15.55 12.85 22.62 13.15 13.29
P/E ratio -12.9 x -7.34 x -9.84 x -1.76 x 85.3 x -0.87 x
Yield - - - - - -
Capitalization / Revenue 0.21 x 0.47 x 0.37 x 0.94 x 0.48 x 0.14 x
EV / Revenue 0.48 x 0.72 x 0.65 x 1.38 x 0.83 x 0.73 x
EV / EBITDA 10.1 x -46.7 x -1.77 x -3.34 x -16.1 x -6.63 x
EV / FCF -8.15 x 29.1 x -4.87 x -668 x -48.9 x -30.6 x
FCF Yield -12.3% 3.43% -20.5% -0.15% -2.04% -3.27%
Price to Book 0.67 x 1.44 x 1.01 x 12.4 x 2.34 x 2.38 x
Nbr of stocks (in thousands) 8,122 9,284 9,634 11,554 12,823 13,400
Reference price 2 0.6061 1.105 0.7600 1.330 0.5900 0.1916
Announcement Date 4/2/18 4/1/19 4/13/20 3/25/21 3/31/22 4/17/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 23.28 21.71 19.84 16.38 15.75 18.12
EBITDA 1 1.105 -0.333 -7.254 -6.769 -0.816 -2.006
EBIT 1 0.463 -0.854 -7.641 -7.114 -1.156 -2.131
Operating Margin 1.99% -3.93% -38.51% -43.43% -7.34% -11.76%
Earnings before Tax (EBT) 1 -0.402 -1.416 -0.727 -7.459 0.099 -2.92
Net income 1 -0.384 -1.339 -0.742 -7.474 0.084 -2.92
Net margin -1.65% -6.17% -3.74% -45.63% 0.53% -16.12%
EPS 2 -0.0469 -0.1505 -0.0773 -0.7551 0.006913 -0.2200
Free Cash Flow 1 -1.374 0.534 -2.638 -0.0339 -0.2688 -0.434
FCF margin -5.9% 2.46% -13.29% -0.21% -1.71% -2.4%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/2/18 4/1/19 4/13/20 3/25/21 3/31/22 4/17/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 6.29 5.29 5.53 7.26 5.59 10.7
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 5.689 x -15.89 x -0.7626 x -1.072 x -6.848 x -5.345 x
Free Cash Flow 1 -1.37 0.53 -2.64 -0.03 -0.27 -0.43
ROE (net income / shareholders' equity) -5.51% -18.4% -10.2% -174% 3.72% -134%
ROA (Net income/ Total Assets) 1.92% -3.47% -28.1% -30.2% -6.27% -9.9%
Assets 1 -20.02 38.6 2.637 24.78 -1.339 29.5
Book Value Per Share 2 0.9000 0.7700 0.7500 0.1100 0.2500 0.0800
Cash Flow per Share 2 0.0200 0.0600 0.0600 0.0100 0.0200 0.0100
Capex 1 0.14 0.08 0.26 0.17 0.03 0.05
Capex / Sales 0.59% 0.37% 1.33% 1.01% 0.2% 0.26%
Announcement Date 4/2/18 4/1/19 4/13/20 3/25/21 3/31/22 4/17/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Equities
  3. BDRL Stock
  4. Financials Blonder Tongue Laboratories, Inc.